Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Big Pharma is facing a looming $236 Billion patent cliff

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Jul 10, 2022 3:31pm

327 Views

Post# 34813975

RE:RE:RE:RE:RE:RE:RE:Big Pharma is facing a looming $236 Billion patent cliff

Agreed cardu. The Parsons addition is just so compelling at this time, with Pfizer having the right of first refusal and Parsons having negotiated a buyout of another biotech with them in recent years. This can't all be mere coincidence...negotiations must be well underway.

<< Previous

Bullboard Posts

Next >>

Junior helium miner will explore record discovery in Q4